From: Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease
Change from baseline at week 49 in
Meaningful improvement
No meaningful improvement or decline
Meaningful decline
FVC, % predicted
Increase ≥ 4%
Increase or decrease < 4%
Decrease ≥ 4%
6MWT
Increase ≥ 39 m
Increase or decrease < 39 m
Decrease ≥ 39 m